T\u00fcrk g\u00f6\u00e7menlerin \u00e7ocuklar\u0131 olan Prof. Dr. U\u011fur \u015eahin ve e\u015fi Dr. \u00d6zlem T\u00fcreci, kurduklar\u0131 biyoteknoloji firmas\u0131yla yeni tip koronavir\u00fcse kar\u015f\u0131 geli\u015ftirilen k\u00fcresel a\u015f\u0131 yar\u0131\u015f\u0131nda ilk s\u0131rada yer al\u0131yor.<\/p>\n
Almanya’da biyoteknoloji firmas\u0131 BioNTech’in yeni tip koronavir\u00fcse (Kovid-19) kar\u015f\u0131 geli\u015ftirmekte oldu\u011fu potansiyel a\u015f\u0131n\u0131n y\u00fczde 90’dan fazla etkili oldu\u011funun a\u00e7\u0131klanmas\u0131yla \u015firketin kurucular\u0131 aras\u0131nda yer alan T\u00fcrk g\u00f6\u00e7menlerin \u00e7ocuklar\u0131 Prof. Dr. U\u011fur \u015eahin ve e\u015fi Dr. \u00d6zlem T\u00fcreci de insanl\u0131\u011fa umut olan bir ba\u015far\u0131ya imza atm\u0131\u015f oldu.<\/p>\n
BioNTech’in, ABD’li orta\u011f\u0131 Pfizer ile \u00f6nceki g\u00fcn yapt\u0131\u011f\u0131 a\u00e7\u0131klamaya g\u00f6re, Kovid-19’a kar\u015f\u0131 geli\u015ftirilen BNT162b2 adl\u0131 a\u015f\u0131 aday\u0131, devam eden 3. a\u015fama denemelerinde y\u00fczde 90’dan fazla etkili oldu\u011funu kan\u0131tlad\u0131. B\u00f6ylelikle ABD G\u0131da ve \u0130la\u00e7 Dairesi’ne (FDA) acil durum onay\u0131 i\u00e7in ba\u015fvuru yap\u0131lmas\u0131n\u0131n \u00f6n\u00fc a\u00e7\u0131ld\u0131.<\/p>\n
T\u00fcrk k\u00f6kenli bir \u00e7iftin kurdu\u011fu Alman biyoteknoloji firmas\u0131 BioNTech, insan sa\u011fl\u0131\u011f\u0131n\u0131 ve ekonomileri tehdit eden Kovid-19 krizini sona erdirecek bir a\u015f\u0131 geli\u015ftirme konusunda k\u00fcresel yar\u0131\u015fta ilk s\u0131raya yerle\u015fti.<\/p>\n
1960’l\u0131 y\u0131llarda T\u00fcrkiye’den Almanya’ya gelen misafir i\u015f\u00e7iler \u00fclkenin refah\u0131na katk\u0131 sa\u011flarken, gurbet\u00e7ilerin bilim insan\u0131 \u00e7ocuklar\u0131 da insanl\u0131\u011fa umut olan bu ba\u015far\u0131yla Almanya’daki T\u00fcrk g\u00f6\u00e7menlerin hem Almanya’ya hem de d\u00fcnyaya ne kadar faydal\u0131 olabilece\u011fini g\u00f6stermi\u015f oldu.<\/p>\n
Prof. Dr. U\u011fur \u015eahin<\/strong> \u00c7ocukken doktor olma hayalleri kuran U\u011fur \u015eahin, K\u00f6ln \u00dcniversitesi’nde t\u0131p e\u011fitimi ald\u0131ktan sonra K\u00f6ln \u00dcniversite Klini\u011fi’nde doktor olarak \u00e7al\u0131\u015ft\u0131. Ard\u0131ndan hocas\u0131 Michael Pfreundschuh ile Homburg’daki Saarland \u00dcniversitesi’ne ge\u00e7en \u015eahin, akademik \u00e7al\u0131\u015fmalar\u0131n\u0131 burada s\u00fcrd\u00fcrd\u00fc. Daha sonra e\u015fi \u00d6zlem T\u00fcreci ile Mainz \u00dcniversitesi’ne ge\u00e7en \u015eahin, onkoloji alan\u0131ndaki bilimsel \u00e7al\u0131\u015fmalar\u0131na hem y\u00f6netici hem de \u00f6\u011fretim g\u00f6revlisi olarak burada devam ediyor.<\/p>\n T\u0131p d\u00fcnyas\u0131nda tan\u0131nan Prof. Dr. U\u011fur \u015eahin, 2019’da ger\u00e7ekle\u015ftirdi\u011fi ara\u015ft\u0131rmalardan dolay\u0131 Alman Kanser Toplumu taraf\u0131ndan \u00f6d\u00fcllendirildi.<\/p>\n Arkada\u015flar\u0131, \u015eahin’i ba\u015far\u0131lar\u0131na ra\u011fmen “inan\u0131lmaz derecede al\u00e7ak g\u00f6n\u00fcll\u00fc ve \u00e7ok m\u00fctevazi” olarak nitelendirirken, i\u015f yerine bisikletle giden \u015eahin’in toplant\u0131lara da elinde bisiklet kask\u0131 ve s\u0131rt \u00e7antas\u0131yla girdi\u011fi belirtiliyor.<\/p>\n Dr. \u00d6zlem T\u00fcreci<\/strong> \u0130stanbul’dan Almanya’ya g\u00f6\u00e7 eden doktor bir baban\u0131n k\u0131z\u0131 olan T\u00fcreci, e\u015fi U\u011fur \u015eahin ile e\u011fitimini tamamlad\u0131\u011f\u0131 Homburg’daki Saaraland \u00dcniversitesi’nde tan\u0131\u015ft\u0131.<\/p>\n Bir r\u00f6portaj\u0131nda, \u00e7ocukken babas\u0131n\u0131n kendisini \u00e7o\u011fu zaman \u00e7al\u0131\u015ft\u0131\u011f\u0131 hastaneye g\u00f6t\u00fcrd\u00fc\u011f\u00fcn\u00fc anlatan T\u00fcreci, \u00e7al\u0131\u015fmay\u0131 \u00e7ok seviyor. T\u00fcreci, belediyede nikahlar\u0131n\u0131n k\u0131y\u0131laca\u011f\u0131 g\u00fcnde bile \u00e7al\u0131\u015fmalar i\u00e7in laboratuvara gittiklerini belirtti.<\/p>\n \u015eahin-T\u00fcreci \u00e7ifti, 2001’de kurduklar\u0131 Ganymed Pharmaceuticals adl\u0131 ilk ortak \u015firketi 2016’da 400 milyon avrodan fazla bir paraya Japon ila\u00e7 \u00fcretici \u015firketi Astellas’a satt\u0131.<\/p>\n Kovid-19’a kar\u015f\u0131 “I\u015f\u0131k H\u0131z\u0131” projesi<\/strong> Ocak 2020’de \u015firketin ara\u015ft\u0131rma ekibini toplayarak a\u015f\u0131 \u00fcretimine odaklanan Prof. Dr. \u015eahin, Kovid-19’a kar\u015f\u0131 “\u0131\u015f\u0131k h\u0131z\u0131yla” bir ila\u00e7 geli\u015ftirmek \u00fczere “Lightspeed (I\u015f\u0131k H\u0131z\u0131)” projesini geli\u015ftirdi.<\/p>\n BioNTech, patojenler yerine hastal\u0131klarla m\u00fccadele eden proteinleri \u00fcretmeleri i\u00e7in h\u00fccrelere talimat vermek \u00fczere genetik materyal kullanan yenilik\u00e7i “mRNA” tekni\u011fi arac\u0131l\u0131\u011f\u0131yla a\u015f\u0131y\u0131 geli\u015ftirmeye odakland\u0131.<\/p>\n BioNTech, kansere kar\u015f\u0131 elde etti\u011fi teknolojiyi Kovid-19 ile sava\u015fa y\u00f6nlendirdi BioNTech, salg\u0131ndan \u00f6nce yakla\u015f\u0131k 1.500 \u00e7al\u0131\u015fan\u0131yla DNA’n\u0131n tek zincirli bir temeli olan mRNA genetik molek\u00fcllere dayal\u0131 olarak kansere kar\u015f\u0131 ila\u00e7 geli\u015ftirme y\u00f6n\u00fcndeki \u00e7al\u0131\u015fmalara odakland\u0131.<\/p>\n \u015eirket, kansere kar\u015f\u0131 elde etti\u011fi bu teknolojisini Kovid-19 ile sava\u015fa y\u00f6nlendirerek geleneksel a\u015f\u0131lardan daha h\u0131zl\u0131 a\u015f\u0131 geli\u015ftirilebilmesi avantaj\u0131 elde etti.<\/p>\n \u015eahin, Alman bas\u0131n\u0131na, mart ay\u0131nda d\u00fcnyan\u0131n b\u00fcy\u00fck bir k\u0131sm\u0131n\u0131n vir\u00fcse kar\u015f\u0131 s\u0131k\u0131 tedbirler uygularken BioNTech’in mRNA teknolojisine dayal\u0131 20 a\u015f\u0131 aday\u0131 geli\u015ftirdi\u011fini s\u00f6yledi.<\/p>\n A\u015f\u0131 adaylar\u0131n\u0131n \u00e7o\u011fu elenirken, BNT162b2 ismi verilen a\u015f\u0131 aday\u0131 Kovid-19’a kar\u015f\u0131 \u00f6ne \u00e7\u0131kt\u0131.<\/p>\n \u015eahin, mRNA tabanl\u0131 bir tedavinin ilk kez ruhsatland\u0131r\u0131lmas\u0131n\u0131n t\u0131p ve eczac\u0131l\u0131k alan\u0131nda bir devrime yol a\u00e7aca\u011f\u0131n\u0131 vurgulad\u0131.<\/p>\n Pfizer ile i\u015f birli\u011fi<\/strong> \u015eirketlerin ortak a\u00e7\u0131klamas\u0131nda, Pfizer’in geli\u015ftirme, d\u00fczenleme ve ticari yetenekleri ile BioNTech’in mRNA a\u015f\u0131 teknolojisi ve uzmanl\u0131\u011f\u0131n\u0131n ortak sinerji olu\u015fturmak i\u00e7in e\u015fle\u015ftirildi\u011fi belirtildi.<\/p>\n Bat\u0131 bas\u0131n\u0131nda, s\u00f6z konusu a\u015f\u0131 aday\u0131nda Pfizer’\u0131n ismi \u00f6ne \u00e7\u0131kart\u0131l\u0131rken, teknolojisinin BioNTech kaynakl\u0131 olmas\u0131 dikkati \u00e7ekti.<\/p>\n Kovid-19 a\u015f\u0131s\u0131n\u0131n bulunmas\u0131 halinde fikri m\u00fclkiyet haklar\u0131n\u0131n BioNTech’in olaca\u011f\u0131 kaydedildi.<\/p>\n Amerikan, \u0130ngiliz, Frans\u0131z, \u0130talyan ve Alman bas\u0131n\u0131nda da “Pandemiye kar\u015f\u0131 sava\u015fanlar”, “Doktor U\u011fur \u015eahin, krizin kurtar\u0131c\u0131s\u0131 m\u0131 olacak?”, “Alman a\u015f\u0131 mucizesinin babas\u0131” \u015feklinde ba\u015fl\u0131klarla \u015eahin ve T\u00fcreci hakk\u0131nda \u00e7ok say\u0131da haber yap\u0131ld\u0131.<\/p>\n Baz\u0131 gazetelerde, \u00e7iftin, t\u0131p alan\u0131nda Nobel \u00d6d\u00fcl\u00fc i\u00e7in favori olabilece\u011fi yorumu da yap\u0131ld\u0131.<\/p>\n Alman h\u00fck\u00fcmetinden 375 milyon avroya kadar destek<\/strong> BioNTech, a\u015f\u0131 \u00fcretimi i\u00e7in merkezi \u0130svi\u00e7re’de bulunan Novartis \u015firketinin Marburg kentinde yer alan ve 300 \u00e7al\u0131\u015fan\u0131 bulunan tesisini sat\u0131n ald\u0131.<\/p>\n 2021’e kadar 1,3 milyar doz a\u015f\u0131 \u00fcretme hedefi<\/strong> Pfizer ve BioNTech, s\u00f6z konusu a\u015f\u0131n\u0131n tedariki i\u00e7in ABD, Avrupa Birli\u011fi (AB), \u0130ngiltere, Kanada ve Japonya ile \u00f6n anla\u015fmalar imzalad\u0131.<\/p>\n \u015eirketler, ABD h\u00fck\u00fcmetine bu y\u0131ldan itibaren 100 milyon doz a\u015f\u0131 sa\u011flamak i\u00e7in 1,95 milyar dolarl\u0131k anla\u015fma yapt\u0131.<\/p>\n AB Komisyonu da 300 milyon doza kadar a\u015f\u0131 almak i\u00e7in bu \u015firketlerle yak\u0131nda nihai s\u00f6zle\u015fme imzalayaca\u011f\u0131n\u0131 duyurdu.<\/p>\n Hisseleri halka arzdan sonra y\u00fczde 600’den fazla artt\u0131 \u015eirketin hisseleri, Kovid-19’a kar\u015f\u0131 geli\u015ftirmekte oldu\u011fu potansiyel a\u015f\u0131n\u0131n vir\u00fcse kar\u015f\u0131 y\u00fczde 90’dan fazla etkili oldu\u011funun a\u00e7\u0131klanmas\u0131n\u0131n ard\u0131ndan y\u00fczde 25’den fazla de\u011fer kazanarak 112 dolar seviyesine y\u00fckseldi. Halka arz sonras\u0131 hisse de\u011fer art\u0131\u015f\u0131 y\u00fczde 600’dan fazla olurken, \u015firketin piyasa de\u011feri de yakla\u015f\u0131k 27 milyar dolara yakla\u015ft\u0131.<\/p>\n S\u00f6z konusu geli\u015fmelerle \u015eahin ve T\u00fcreci, Almanya’da en zengin 100 ki\u015fi aras\u0131na girdi.<\/strong><\/p>\n BioNTech, gelecek y\u0131l a\u015f\u0131 sat\u0131\u015f\u0131ndan 13 milyar dolar gelir elde edebilir \u0130ki doz halinde uygulanan s\u00f6z konusu a\u015f\u0131 aday\u0131n\u0131n ABD h\u00fck\u00fcmetiyle tedariki konusunda yap\u0131lan anla\u015fmada 39 dolar (her doz a\u015f\u0131 i\u00e7in 19,5 dolar) fiyat belirlenmi\u015fti.<\/p>\n","protected":false},"excerpt":{"rendered":" T\u00fcrk g\u00f6\u00e7menlerin \u00e7ocuklar\u0131 olan Prof. Dr. U\u011fur \u015eahin ve e\u015fi Dr. \u00d6zlem T\u00fcreci, kurduklar\u0131 biyoteknoloji firmas\u0131yla yeni tip koronavir\u00fcse kar\u015f\u0131 geli\u015ftirilen k\u00fcresel a\u015f\u0131 yar\u0131\u015f\u0131nda ilk s\u0131rada yer al\u0131yor. Almanya’da biyoteknoloji firmas\u0131 BioNTech’in yeni tip koronavir\u00fcse (Kovid-19) kar\u015f\u0131 geli\u015ftirmekte oldu\u011fu potansiyel a\u015f\u0131n\u0131n y\u00fczde 90’dan fazla etkili oldu\u011funun a\u00e7\u0131klanmas\u0131yla \u015firketin kurucular\u0131 aras\u0131nda yer alan T\u00fcrk g\u00f6\u00e7menlerin \u00e7ocuklar\u0131 …<\/p>\n","protected":false},"author":1,"featured_media":29898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[424],"class_list":["post-29897","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dunya-gundem","tag-biontech"],"yoast_head":"\n
\n1965’te \u0130skenderun’da do\u011fan U\u011fur \u015eahin, 4 ya\u015f\u0131ndayken annesiyle birlikte Almanya’da Ford fabrikas\u0131nda \u00e7al\u0131\u015fan babas\u0131n\u0131n yan\u0131na (K\u00f6ln) g\u00f6\u00e7 etti.<\/p>\n
\nBioNTech’in kurucular\u0131ndan Prof. Dr. U\u011fur \u015eahin’\u0131n e\u015fi Dr. \u00d6zlem T\u00fcreci de \u015firkette 10 y\u0131l Klinik ve Bilimsel Dan\u0131\u015fma Kurulu \u00fcyeli\u011fi yapt\u0131ktan sonra 2018’de BioNTech’te Y\u00f6netim Kurulu \u00dcyesi oldu. T\u00fcreci, “t\u0131bbi idareci (chief medical officier)” olarak klinik geli\u015fim b\u00f6l\u00fcm\u00fcn\u00fc de y\u00f6netmeye ba\u015flad\u0131.<\/p>\n
\nKovid-19 salg\u0131n\u0131n\u0131n \u00c7in’in Hubey eyaletinde patlak vermesi \u00fczerine harekete ge\u00e7en \u015eahin ve T\u00fcreci, BioNTech \u015firketindeki kanser ara\u015ft\u0131rmalar\u0131na ara verdi.<\/p>\n
\nAlmanya’n\u0131n Mainz kentinde faaliyet g\u00f6steren BioNTech, 2008’de \u015eahin, T\u00fcreci ve Avusturyal\u0131 kanser uzman\u0131 Christoph Huber taraf\u0131ndan kuruldu.<\/p>\n
\nABD ila\u00e7 devi Pfizer ile 2018’de grip a\u015f\u0131lar\u0131n\u0131n geli\u015ftirilmesi konusunda i\u015f birli\u011fi anla\u015fmas\u0131 imzalayan BioNTech, Pfizer ile i\u015f birli\u011fini art\u0131rarak, 17 Mart’ta, mRNA tabanl\u0131 BNT162b2 a\u015f\u0131s\u0131n\u0131n geli\u015ftirilmesinde ortak \u00e7al\u0131\u015facaklar\u0131n\u0131 duyurdu.<\/p>\n
\nKovid-19 tedavisine y\u00f6nelik a\u015f\u0131n\u0131n “h\u0131zl\u0131 geli\u015fimini” desteklemek amac\u0131yla Alman h\u00fck\u00fcmeti taraf\u0131ndan 375 milyon avroya kadar desteklenen BioNTech, mart ay\u0131nda, \u00c7in merkezli Shanghai Fosun Pharmaceutical (Fosun Pharma) ile BNT162b2 a\u015f\u0131s\u0131n\u0131n geli\u015ftirilmesi, klinik testlerinin yap\u0131lmas\u0131 ve \u00c7in’de pazarlanmas\u0131na y\u00f6nelik de i\u015f birli\u011fi anla\u015fmas\u0131 yapt\u0131.<\/p>\n
\nBir\u00e7ok \u00fclke, milyonlarca a\u015f\u0131 dozu i\u00e7in s\u00f6zle\u015fme imzalama yar\u0131\u015f\u0131na girerken, BioNTech, orta\u011f\u0131 Pfizer ile 2020 sonuna kadar 100 milyon ve 2021’de de yakla\u015f\u0131k 1,3 milyar doz a\u015f\u0131 \u00fcretmeyi planl\u0131yor.<\/p>\n
\nHisseleri Ekim 2019’da ABD’de Nasdaq borsas\u0131nda halka arz edilen BioNTech, planlanandan d\u00fc\u015f\u00fck fiyatla beklenenden daha az hisse satarak 150 milyon dolar toplam\u0131\u015ft\u0131. Halka arz sonras\u0131 \u015firketin de\u011feri 3,4 milyar dolar olarak a\u00e7\u0131klanm\u0131\u015ft\u0131. \u015eirketin 2019 gelirleri 109 milyon dolar olarak kay\u0131tlara ge\u00e7ti.<\/p>\n
\nBu arada, ABD’li yat\u0131r\u0131m bankac\u0131l\u0131\u011f\u0131 ve finansal hizmetler kurulu\u015fu Morgan Stanley’in yapt\u0131\u011f\u0131 analize g\u00f6re, Pfizer ve BioNTech, gelecek y\u0131l Kovid-19 doz a\u015f\u0131n\u0131n sat\u0131\u015f\u0131ndan yakla\u015f\u0131k 13 milyar dolar gelir elde edebilir.<\/p>\n